Revenue
$56.01M
Fiscal year ended 2026-06-30Operating income
-$4.81M
Fiscal year ended 2026-06-30Free cash flow
-$768.00K
Fiscal year ended 2026-06-30Valuation, from the filing
| Public float | $800.00M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $18.11 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / revenue | 4.0× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 4.5× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
How this compares in its industry
Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| Current ratio | 8.55x | 89th | |
| Gross margin | 79.6% | 86th | |
| Long-term debt / equity | 0.20x | 28th | |
| Revenue YoY growth | 20.2% | 68th | |
| SBC / revenue | 12.7% | 64th | |
| Net margin | -9.4% | 63th | |
| R&D / revenue | 8.7% | 37th | |
| CapEx / revenue | 4.2% | 57th | |
| Operating margin | -11.1% | 56th | |
| FCF margin | -4.5% | 53th |
SI-BONE, Inc. (SIBN) reported revenue of $56.01M and net income of -$4.09M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from SI-BONE, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.01M | $52.59M | $56.35M | $48.66M | $48.63M | $47.29M | $49.00M | $40.34M | $39.97M | $37.87M |
| Cost of revenue | $11.46M | $10.64M | $11.82M | $9.81M | $9.82M | $9.60M | $10.22M | $8.44M | $8.39M | $8.00M |
| Gross profit | $44.55M | $41.94M | $44.53M | $38.85M | $38.81M | $37.70M | $38.78M | $31.90M | $31.58M | $29.86M |
| Operating income | -$4.81M | -$5.09M | -$2.46M | -$5.38M | -$7.00M | -$7.48M | -$5.49M | -$7.63M | -$10.08M | -$12.04M |
| Net income | -$4.09M | -$4.33M | -$1.64M | -$4.57M | -$6.15M | -$6.54M | -$4.50M | -$6.58M | -$8.94M | -$10.90M |
| Research & development | $5.22M | $4.19M | $4.36M | $4.24M | $4.31M | $4.53M | $3.87M | $3.99M | $4.35M | $4.34M |
| Weighted-average diluted shares | shares 44.48M | shares 43.96M | Unavailable | shares 43.19M | shares 42.79M | shares 42.34M | Unavailable | shares 41.72M | shares 41.32M | shares 40.93M |
| Pretax income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Diluted EPS | $-0.09 | $-0.10 | Unavailable | $-0.11 | $-0.14 | $-0.15 | Unavailable | $-0.16 | $-0.22 | $-0.27 |
| Selling, general & administrative | $44.13M | $42.84M | $42.63M | $39.99M | $41.50M | $40.64M | $40.40M | $35.54M | $37.30M | $37.56M |
| General & administrative | $10.11M | $10.04M | $9.82M | $10.03M | $10.72M | $9.96M | $9.15M | $8.10M | $8.33M | $8.18M |
| Selling & marketing | $34.02M | $32.81M | $32.81M | $29.96M | $30.78M | $30.68M | $31.25M | $27.45M | $28.97M | $29.39M |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $33.13M | $33.54M | $42.24M | $26.49M | $34.15M | $41.19M | $34.95M | $30.22M | $25.58M | $32.04M |
| Total assets | $248.76M | $242.72M | $238.56M | $234.27M | $230.92M | $227.28M | $230.44M | $227.00M | $223.84M | $223.71M |
| Current assets | $219.91M | $214.72M | $216.12M | $210.78M | $207.45M | $204.20M | $207.78M | $203.70M | $202.33M | $203.63M |
| Total liabilities | $66.41M | $63.78M | $61.02M | $62.15M | $60.58M | $60.02M | $63.47M | $62.02M | $59.11M | $58.18M |
| Current liabilities | $24.04M | $21.49M | $25.28M | $26.44M | $24.75M | $23.95M | $27.13M | $24.68M | $22.06M | $20.86M |
| Total equity incl. NCI | $182.35M | $178.94M | $177.53M | $172.13M | $170.34M | $167.26M | $166.96M | $164.97M | $164.73M | $165.54M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $38.39M | $35.53M | $33.90M | $35.73M | $34.24M | $30.38M | $27.07M | $25.52M | $23.23M | $21.05M |
| Accounts receivable | $31.18M | $30.96M | $29.92M | $26.53M | $24.37M | $26.70M | $27.46M | $24.91M | $24.80M | $22.11M |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | $35.63M | $35.60M | $35.57M | $35.54M | $35.51M | $35.48M | $35.45M | $36.19M | $36.15M | $36.11M |
| Accounts payable | $8.54M | $6.76M | $4.63M | $7.72M | $7.50M | $7.70M | $6.49M | $7.32M | $7.18M | $7.66M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $777.00K | -$2.36M | $1.73M | $2.34M | $173.00K | -$4.91M | $1.18M | $302.00K | -$6.33M | -$7.57M |
| Capital expenditures | $1.54M | $1.08M | $1.29M | $2.96M | $2.10M | $2.07M | $2.27M | $3.04M | $3.11M | $2.08M |
| Investing cash flow | -$2.74M | -$6.23M | $13.03M | -$10.02M | -$9.47M | $10.63M | $4.34M | $3.77M | -$1.83M | $6.35M |
| Financing cash flow | $1.63M | $34.00K | $1.03M | $11.00K | $2.23M | $103.00K | -$78.00K | $155.00K | $1.78M | $105.00K |
| Net change in cash | -$407.00K | -$8.70M | $15.75M | -$7.66M | -$7.04M | $6.24M | $4.72M | $4.65M | -$6.46M | -$1.23M |
| Stock-based compensation | $5.98M | $6.02M | $5.98M | $6.23M | $6.66M | $6.66M | $6.14M | $6.31M | $6.40M | $7.03M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $1.68M | $1.62M | $1.64M | $1.49M | $1.37M | $1.28M | $1.21M | $1.08M | $992.00K | $1.09M |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | -$768.00K | -$3.44M | $440.00K | -$620.00K | -$1.93M | -$6.98M | -$1.09M | -$2.73M | -$9.45M | -$9.65M |
| Gross margin | 79.5% | 79.8% | 79.0% | 79.8% | 79.8% | 79.7% | 79.1% | 79.1% | 79.0% | 78.9% |
| Operating margin | -8.6% | -9.7% | -4.4% | -11.1% | -14.4% | -15.8% | -11.2% | -18.9% | -25.2% | -31.8% |
| FCF margin | -1.4% | -6.5% | 0.8% | -1.3% | -4.0% | -14.8% | -2.2% | -6.8% | -23.6% | -25.5% |
| SBC / revenue | 10.7% | 11.5% | 10.6% | 12.8% | 13.7% | 14.1% | 12.5% | 15.6% | 16.0% | 18.6% |
| Current ratio | 9.15x | 9.99x | 8.55x | 7.97x | 8.38x | 8.53x | 7.66x | 8.25x | 9.17x | 9.76x |
| Revenue YoY growth | 15.2% | 11.2% | 15.0% | 20.6% | 21.7% | 24.9% | 26.1% | 18.6% | 20.0% | 15.8% |
| Net margin | -7.3% | Unavailable | -2.9% | -9.4% | -12.7% | Unavailable | -9.2% | -16.3% | Unavailable | Unavailable |
| R&D / revenue | 9.3% | 8.0% | 7.7% | 8.7% | 8.9% | 9.6% | 7.9% | 9.9% | 10.9% | 11.5% |
| CapEx / revenue | 2.8% | 2.0% | 2.3% | 6.1% | 4.3% | 4.4% | 4.6% | 7.5% | 7.8% | 5.5% |
| Long-term debt / equity | 0.20x | Unavailable | 0.20x | 0.21x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SIBN in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.